Immunization with recombinant LD1 antigens protects against experimental leishmaniasis

Vaccine

Volumn 19, Issue 4-5, 2000, Pages 423-430

  Dole, Vandana S ^a   Raj, V Samuel ^a   Ghosh, Anirban ^a   Madhubala, Rentala ^a   Myler, Peter J ^b,c   Stuart, Kenneth D ^b,c  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Leishmania donovani; Recombinant antigen; Vaccination

Indexed keywords

FREUND ADJUVANT; LEISHMANIA VACCINE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; IMMUNIZATION; IMMUNOGENICITY; LEISHMANIA DONOVANI; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMAL; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; GENES, PROTOZOAN; IMMUNIZATION; IN VITRO; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MULTIGENE FAMILY; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0034668153     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00207-3     Document Type: Article

References (47)

1. Jaffe C.L., Greenblatt C.L. Vaccine development against the intracellular parasite Leishmania. Cryz S.J. Jr. Vaccines and immunotherapy. 1991;38 Pergamon Press, London, UK.
2. Ridley D. Pathobiology. Peters W., Killick-Kendrick R. The leishmaniases in biology and medicine. 1987;665-701 Academic Press, London.
3. Evans T.G., Krug E.C., Wilson M.E., Vasconcelos A.W., de Alencar J.E., Pearson R.D. Evaluation of antibody responses in American visceral leishmaniasis by ELISA and immunoblot. Mem. Inst. Oswaldo Cruz. 84:1989;157-166.
4. Galvao-Castro B., Sa F.J., Marzochi K.F., Marzochi M.C., Coutinho S.G., Lambert P.H. Polyclonal B cell activation, circulating immune complexes and autoimmunity in human American visceral leishmaniasis. Clin. Exp. Immunol. 56:1984;58-66.
5. Ho J.L., Badaro R., Schwartz A., et al. Diminished in vitro production of interleukin-1 and tumor necrosis factor-β during acute visceral leishmaniasis and recovery after therapy. J. Infect. Dis. 165:1992;1094-1102.
6. Murray H.W., Stern J.J., Welte K., Rubin B.Y., Carriero B.Y., Nathan C.F. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-γ, tissue immune reaction, and response to treatment with interleukin 2 and interferon-γ J. Immunol. 138:1987;2290-2297.
7. Carvalho E.M., Bacellar O., Brownell C., Regis T., Coffman R.L., Reed S.G. Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 152:1994;5949-5956.
8. Nabors G.S. Modulating the Th-2 cell reponses in experimental leishmaniasis. Parasitol. Today. 13:1997;76-79.
9. Howard J.G. Immunological regulation and control of experimental leishmaniasis. Int. Rev. Exp. Pathol. 28:1986;79-116.
10. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon-γ or interleukin-4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T-cell subsets. J. Exp. Med. 169:1989;59-72.
11. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. USA. 88:1991;7011-7015.
12. Locksley R.M., Scott P. Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. Immunol. Today. 12:(3):1991;A58-61.
13. Scott P., Natovitz P., Coffman R.L., Pearce E., Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med. 168:1988;1675-1684.
14. Kaye P.M., Curry A.J., Blackwell J.M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146:1991;2763-2770.
15. Carvalho E.M., Barral A., Pedral-Sampaio D., et al. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J. Infect. Dis. 165:1992;535-540.
16. + T cells in intracellular infections in humans: leishmaniasis as an example. Immunol. Today. 17:1996;13-16.
17. Karp C.L., El-Safi S.H., Wynn T.A., et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-γ J. Clin. Invest. 91:1993;1644-1648.
18. Kemp M., Kurtzhals J.A., Bendtzen K., et al. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect. Immun. 61:1993;1069-1073.
19. Handman E. Leishmania vaccines: old and new. Parasitol. Today. 13:1997;236-238.
20. Jahn A., Lelmett J.M., Diesfeld H.J. Seroepidemiological study on kala-azar in Baringo District. Kenya. J. Trop. Med. Hyg. 89:1986;91-104.
21. Jaffe C.L., Rachamim N., Sarfstein R. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J. Immunol. 144:1990;699-706.
22. Rachamim N., Jaffe C.L. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:1993;2322-2331.
23. Santos W.R., Paraguai de Souza E., Palatnik M., Palatnik de Sousa C.B. Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani. Vaccine. 17:(20-21):1999;2554-2561.
24. Tripp C.A., Myler P.J., Stuart K. A DNA sequence (LD1) which occurs in several genomic organizations in Leishmania. Mol. Biochem. Parasitol. 47:1991;151-160.
25. Lodes M.J., Merlin G., deVos T., et al. Increased expression of LD1 genes transcribed by RNA polymerase I in Leishmania donovani as a result of duplication into the rRNA gene locus. Mol. Cell. Biol. 15:1995;6845-6853.
26. Segovia M., Ortiz G. LD1 amplification in Leishmania. Parasitol. Today. 13:1997;342-348.
27. Kundig C., Haimeur A., Legare D., Papadopoulou B., Ouellette M. Increased transport of pteridines compensates for mutations in the high affinity folate trasporter and contributes to methotrexate resistance in the protozoan parasite Leishmania tarentolae. EMBO J. 18:1999;2342-2351.
28. Lemley C, Yan S, Dole VS, Madhubala R, Cunningham ML, Beverley SM, Myler PJ, Stuart, KD, The Leishmania donovani LD1 locus gene ORFG encodes a biopterin transporter (BT1). Mol Biochem Parasitol, 1999;104:93-105.
29. Ghosh A., Madhubala R., Myler P.J., Stuart K.D. Leishmania donovani: characterization and expression of ORFF, a gene amplified from the LD1 locus. Expt. Parasitol. 93:1999;225-234.
30. Raj V.S., Ghosh A., Dole V.S., Madhubala R., Myler P.J., Stuart K.D. Serodiagnosis of leishmaniasis with recombinant ORFF antigen. Am. J. Trop. Med. Hyg. 61:(3):1999;482-487.
31. Hart D.T., Vickerman K., Coombs G.H. A quick, simple method for purifying Leishmania mexicana amastigotes in large numbers. Parasitology. 82:1981;345-355.
32. Tripp C.A., Wisdom W.A., Myler P.J., Stuart K. A multicopy, extrachromosomal DNA in Leishmania infantum contains two inverted repeats of the 27.5 kb LD1 sequence and encodes numerous transcripts. Mol. Biochem. Parasitol. 55:1992;39-50.
33. Murray P.D. Maintaining protein stability. Drutscher M. Methods in enzymology. 1990;83-92 Academic Press, London, UK.
34. Stauber L.A., Franchino E.M., Grun J. An eight day method for screening compounds against Leishmania donovani in golden hamsters. J. Protozool. 5:1958;269-273.
35. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA. 76:1979;4350-4354.
36. Fisher R.A., Yates F. Students t-test of significance. Statistical tables for agricultural and other researh workers. 1957;1024-1029 Oliver and Boyd, Edinburgh.
37. Blackwell J.M., Roberts B., Alexander J. Response of BALB/c mice to leishmanial infection. Curr. Top. Microbiol. Immunol. 122:1985;97-106.
38. Wilson M.F., Young M.B., Andersen K.P., Weinstock J.V., Metwall A., Ali K.M., Donelson J.E. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect. Immun. 63:1995;2062-2069.
39. Ulczak O.M., Blackwell J.M. Immunoregulation of genetically controlled acquired responses to Leishmania donovani infection in mice: the effects of parasite dose, cyclophosphamide and sublethal irradiation. Parasite Immunol. 5:1983;449-463.
40. Green S.J., Meltzer M.S., Hibbs J.B.J., Nacy C.A. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J. Immunol. 144:1990;278-283.
41. Murray H.W., Spitalny G.L., Nathan C.F. Activation of mouse peritonial macrophages in vitro and in vivo with interferon-gamma. J. Immunol. 134:1985;1619-1622.
42. Mendonca S.C., Russell D.G., Coutinho S.G. Analysis of the human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp63). Clin. Exp. Immunol. 83:1991;472-478.
43. Yang D.M., Fairweather N., Button L.L., McMaster W.R., Kahl L.P., Liew F.Y. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J. Immunol. 145:1990;2281-2285.
44. Russo D.M., Turco S.J., Burns J.M. Jr., Reed S.G. Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins. J. Immunol. 148:1992;202-307.
45. White A.C.J., McMahon-Pratt D. Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine. J. Infect. Dis. 161:1990;1313-1314.
46. Burns J.M. Jr., Scott J.M., Carvalho E.M., et al. Characterization of a membrane antigen of Leishmania amazonensis that stimulates human immune responses. J. Immunol. 146:1991;742-748.
47. Champsi J., McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 56:1988;3272-3279.